Kahn Partners served as lead M&A counsel to Eurobio Scientific (Euronext Growth Paris: ALERS) in its agreement to acquire the Lab Products division of CareDx, Inc. (Nasdaq: CDNA), a U.S. precision medicine company focused on transplantation, in an all-cash transaction valued at $170 million.
The acquisition brings together two highly complementary portfolios in HLA typing and transplant monitoring, creating one of the most comprehensive offerings in the industry, from pre-transplant typing to post-transplant monitoring.
The transaction involved complex regulatory matters, cross-border structuring and carve-out mechanics across multiple jurisdictions.
The Kahn Partners team was led by William Kahn (Partner, Corporate / M&A), with Zachary Kline (Counsel, Intellectual Property), Ashkon Roozbehani (Counsel, Employment and Benefits), Melanie Cristol (Counsel, Trade and Regulatory) and Ruben Gandanger (M&A Analyst).
Read the full announcement (PDF)
Update: the transaction closed on 30 June 2026.